Generation of monoclonal antibodies against PBP2a to improve diagnosis and potential treatment of MRSA infections

Background: MRSA is a type of MDR bacterium. All around the world, it leads to significant nosocomial and community-acquired diseases. The discovery fresh ideas very important because there are so few effective treatments for infections. PBP2a great candidate development MRSA-specific Mabs. Aim: purpose this study was create murine Mabs against in order enhance laboratory detection possibly treatment. Methods: Anti-PBP2a MAb tested biodistribution, therapeutic, preventative effects comparison vancomycin. After receiving anti-PBP2a therapy, biodistribution assessed between 12 96 hours later. Results: During observation timepoints, majority generated stayed serum just tiny fraction found kidneys, lungs, spleen. A prophylactic experiment mice given lethal dosage 50 (LD50) that treated animals with had greater survival rate than control group. In therapeutic experiment, one reduced bacterial load kidneys similarly group five doses vancomycin, combination therapy vancomycin more either drug used alone. Conclusion: findings suggested an may be extremely useful creation innovative diagnostic tools promising measures